111 Capital’s Amicus Therapeutics FOLD Stock Holding History

111 Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,355	Closed	-$76.5K	–	551
2025 Q2	$76.5K	Buy	+13,355	New	+$86.2K	0.01%	488

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

111 Capital's FOLD Position: Q3 2025 in Review

111 Capital sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 13,355 shares — an estimated $76.5K sold.

111 Capital first reported a position in FOLD in Q2 2025 and held it in 1 quarter. The position peaked at $76.5K in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

111 Capital reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 13,355 Amicus Therapeutics shares in Q3 2025, an estimated $76.5K.
111 Capital first reported a position in Amicus Therapeutics in Q2 2025 and held it in 1 quarter.
111 Capital's Amicus Therapeutics position peaked at $76.5K in Q2 2025.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.